A Decade of Data Shows the Value of Isoray's Cesium-131 As Prostate Cancer Internal Radiation Therapy Treatment

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022
Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.
Isoray Completes Merger with Viewpoint Molecular Targeting to Advance New Treatment Paradigm in Targeted Precision Oncology Medicine
Isoray Announces Results of Fiscal 2023 Annual Meeting of Stockholders
Isoray Announces Adjournment of Annual Meeting of Stockholders to January 27, 2023
AMENDED: Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2023
Isoray Announces Adjournment of Annual Meeting of Stockholders to January 12, 2022
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ISR, SLDB, POSH, OFIX

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.